Using human serum albumin to improve outcomes after stroke surgery

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This project investigates the effects of human serum albumin on reducing postoperative cerebral edema and improving clinical outcomes in patients who have undergone mechanical thrombectomy for acute large-core ischemic stroke. The study focuses on patients with anterior circulation strokes and aims to understand how albumin can enhance neuroprotection by improving microcirculation and reducing inflammation. Participants will receive an intravenous infusion of human albumin shortly after their surgical procedure to assess its therapeutic efficacy.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age 18-80 years old.
2. Acute ischemic stroke patients with NIHSS score ≥ 6.
3. Pre-stroke mRS (modified Rankin Scale) score ≤ 1.
4. Onset of symptoms to presentation within 24 hours, including wake-up strokes or strokes without witnessed onset; the time of symptom onset is defined as the "last seen normal" time.
5. Confirmed by CTA/MRA/DSA to have anterior circulation large vessel occlusive ischemic stroke (occlusion of the internal carotid artery or M1 or M2 segments of the middle cerebral artery), responsible for acute ischemic stroke signs and symptoms.
6. ASPECTS (Alberta Stroke Program Early CT Score) on NCCT (non-contrast CT) 3-6 or cerebral perfusion imaging: core infarct volume (rCBF ≤ 30%) 50-100 ml.
7. Achieving vessel reperfusion of mTICI (modified Thrombolysis in Cerebral Infarction) grade 2b or 3 through mechanical thrombectomy.
8. Written informed consent signed by the patient or their legally authorized representative.

Exclusion Criteria:

1. Intracranial hemorrhage confirmed by head CT or MRI.
2. Pre-stroke mRS score \> 2.
3. Severe allergy or absolute contraindication to iodine-based contrast agents.
4. Systolic blood pressure \> 185 mmHg or diastolic blood pressure \> 110 mmHg, and inability to control with antihypertensive medication.
5. Blood glucose \< 50 mg/dl (2.8 mmol/L) or \> 400 mg/dl (22.2 mmol/L) and difficult to correct.
6. Genetic or acquired bleeding diathesis, deficiency of coagulation factors, or oral anticoagulation with INR \> 1.7.
7. Severe renal dysfunction defined as serum creatinine \> 3.0 mg/dl (or 265.2 μmol/l) or glomerular filtration rate (GFR) \< 30 ml/min, or need for hemodialysis or peritoneal dialysis.
8. Expected life expectancy \< 6 months.
9. Anticipated inability of the patient to complete the 90-day follow-up.
10. Suspected aortic dissection.
11. Brain tumors, intracranial aneurysms, or arteriovenous malformations with mass effect on imaging.
12. Neurological or psychiatric disorders affecting the assessment of the disease before the patient's stroke.
13. Pregnancy or reproductive-age women with positive urinary or serum β-human chorionic gonadotropin (HCG) test.
14. Currently participating in other clinical trials that may interfere with the results of this trial.
15. History of allergy to albumin.
16. Need for intermittent or long-term concomitant acute or chronic pulmonary diseases.
17. Congestive heart failure for any reason in the past 6 months or any condition requiring medication, hospitalization, etc., related to heart failure.
18. Symptomatic or diagnosed acute myocardial infarction, or occurrence of acute myocardial infarction within the past 6 months.
19. Other situations that the investigator believes are not suitable for participation or may pose significant risks to the patient.

Where it's running

• Zhangzhou Municipal Hospital
  Zhangzhou, Fujian, China Recruiting

Study contacts

• Principal investigator: Tingyu Yi, Postgraduate — zhangzhou Affiliated Hospital to Fujian Medical University , Fujian ,China
• Study coordinator: Tingyu Yi, Postgraduate
• Email: siyuyufen@163.com
• Phone: +86-05962082582

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Ultrasound versus CT for measuring brain blood flow after subarachnoid hemorrhage

  This will test whether contrast-enhanced bedside ultrasound can show brain blood flow as well as routine perfusion CT in adults in the neuro ICU with subarachnoid hemorrhage or other acute brain injury.

  Recruiting Resolve Stroke · Montpellier, Herault · NCT07324421

• Infusing healthy mitochondria to treat cerebral ischemia

  This study is testing whether infusing healthy mitochondria into the brain can help patients with reduced blood flow during a specific treatment for stroke.

  Recruiting University of Washington · Seattle, Washington · NCT04998357

• Using xenon to protect the brain after aneurysmal subarachnoid hemorrhage

  This study is testing if inhaling xenon gas can help protect the brains of people who have had a brain bleed from an aneurysm.

  Recruiting Phase 2 Turku University Hospital · Helsinki, Helsinki and 6 other locations · NCT04696523

• Evaluating cerebral blood flow using a new method from angiography

  This study is trying to see if a new way of looking at brain blood flow from angiography can help predict recovery in patients who have had a stroke caused by blocked blood vessels.

  Recruiting Xi'an No.3 Hospital · Xi'an, Shaanxi · NCT03607565

• Registry connecting stroke survivors with research opportunities

  This study connects stroke survivors with research opportunities to help find new treatments that can improve their recovery.

  Recruiting University of California, San Francisco · San Francisco, California · NCT03318432

• Treatment for neurologic disorders using stem cells

  This study is testing whether using stem cells from patients' own bone marrow can help improve brain and nerve function in people with serious neurologic disorders that don't respond well to regular treatments.

  Recruiting at 3 sites MD Stem Cells · Westport, Connecticut and 2 other locations · NCT02795052

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.